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Background: Disease phenotype in cystic fibrosis (CF) shows considerable heterogeneity. Atypical or mild mutations in the CFTR gene
have been linked to late-onset pulmonary disease; however, few reports document the condition of the airway in infants and young children
with apparent ‘‘mild’’ disease. Prognosis is uncertain in this group of patients and this, in turn, has led to inconsistency in management. Our
initial experience of pulmonary infection in children with mild variant CF prompted a more detailed review of clinical outcome.
Methods: A retrospective cohort study was carried out comparing frequency of bacterial isolates and clinical outcomes in eleven compound
heterozygotes for DF508 and a second mild mutation, mainly R117H, with a matched group of DF508 homozygotes.
Results: Staphylococcus aureus was isolated in 8 of the 11 patients with mild variant disease and Pseudomonas aeruginosa found in 7
(64%), although the frequency of positive cultures was significantly less (2.8/year) than the DF508 homozygotes (6.1/year, p <0.05).
Shwachman scores (median+range) were significantly higher in patients with mild mutations — 94, 74–92 vs. 88, 77–91; p <0.005); there
was also a small but significant difference in chest radiograph (Chrispin–Norman) scores (median+range) (mild 5.1, 4–9, vs. severe 5.8, 3–
10; p 0.04). There was little difference in lung function in terms of FEV1 (median+range) between the two groups (% predicted, mild 86.5,
68–87 vs. severe 76.0, 65–88; p 0.5).
Conclusions: Most patients with mild variant CF will have bacterial isolates from airway cultures requiring antibiotic therapy three to four
times a year. Infection with both S. aureus and P. aeruginosa is common. Anti-staphylococcal prophylaxis for the first two years should be
considered.
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transmembrane conductance regulator (CFTR) gene which
encodes a protein expressed in the apical membrane of
exocrine epithelial cells. Five classes of mutation have been
identified. Types I, II and III are classified as severe and
associated with the classic phenotype of sino-pulmonary
disease and pancreatic insufficiency; types IV and V are
classed as mild and associated with a variable phenotype,
pancreatic sufficiency and borderline or normal sweat
electrolyte concentrations [1]. As genetic diagnosis becomes
more common, patients with such mild phenotypes are
being increasingly recognised, many presenting in infancy
as the result of postnatal screening programmes. Prognosis1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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E-mail address: c.j.taylor1@sheffield.ac.uk (C.J. Taylor).is uncertain in this group of patients and this, in turn, has led
to inconsistency in management. For example, Chmiel et al.
expressed their doubts over diagnosing CF in an asymp-
tomatic infant with a DF508/R117H genotype [2]. Others
have noted considerable heterogeneity in the phenotype of
patients with mild mutations [3]. A single retrospective
cohort study has documented a significant mortality rate
(4.4–11.9, respectively) associated with four relatively
common mild mutations [4].
Our initial experience of CF patients with mild muta-
tions, the majority of whom were identified through a
neonatal screening programme, suggested that bacterial
respiratory infection with typical CF pathogens was not
unusual [5]. Thus, routine review with regular sputum
cultures was advisable. We now report our experience in a
larger cohort of patients who have attended clinic regularly
from the time of diagnosis.5 (2006) 101 – 104ed by Elsevier B.V. All rights reserved.
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A retrospective cohort study was carried out assessing
frequency of bacterial isolates and clinical outcomes in a
group of eleven patients (4 male) who were compound
heterozygotes for the DF508 mutation and a second mild
mutation, mainly R117H (Table 1a). Seven of the eleven
were identified by postnatal screening with high immuno-
reactive trypsin concentrations; of the remaining 4, two
were first degree relatives of CF affected patients and two
had suggestive symptomatology including one infant with
bilateral absence of the vas deferens. All eleven subjects
were pancreatic sufficient with pancreatic Elastase1 values
>200 Ag/g stool. This cohort comprises all patients with
mild variant disease under regular clinic review. Compar-
isons were made with an age and sex matched group of
DF508 homozygotes (Table 1b).
Patients have been under review for between one and
seven years with a mean follow up of 5.2 years. All
children had attended the chest clinic at Sheffield Child-
ren’s Hospital on a six to twelve week basis with naso-
pharyngeal aspirates/cough swabs/sputum cultures (age
dependent) obtained at each visit by a CF physiotherapist.
Respiratory specimens were cultured using standard
techniques. Briefly, freshly collected sputum, cough swabs
or lavage samples were cultured using several selective or
enriched media as per UKCF Trust recommendations [6].
Plates were read at 24 and 48 h using standard
microbiological techniques. B. cepacia plates were reincu-
bated and read at 5 days. First isolates of P. aeruginosa
and all probable B. cepacia isolates were sent to the
National Reference Laboratory, Edinburgh, UK for confir-
mation and typing. Anti-staphylococcal prophylaxis was
routine to 5 years for patients with classic disease but was
only prescribed for 7 children with mild variant disease; of
these only 4 received prophylactic antibiotics during the
first year of life. Shwachman [7] and Chrispin–Norman
[8] scores were derived from the annual review data. Lung
function was performed using a Vitalograph Spirotrac IIITable 1a
Patient details for mild variant cohort
Age
(years)
Sex Genotype Splice site
marker
Sweat
Na+/Cl
(mmol/l)
A
S
s
3 Male dF508/R117H 7T/9T 9
5 Male dF508/R117H 7T/9T 9
7 Female dF508/R117H 7T/9T 51/49 9
11 Female dF508/3849+10 kb C>T Unknown 30/36 7
7 Female dF508/R117H 7T/9T 74/75 9
1 Male dF508/R117H 7T/9T
4 Female dF508/R117H 7T/9T 9
5 Female dF508/R117H 7T/9T 31/28 9
6 Female dF508/R117H 7T/9T 42/38 9
7 Male dF508/R117H 7T/9T 42/28 9
7 Female dF508/R117H 7T/7T 50/40 9
a Culture samples based on naso-pharyngeal aspirates/cough swabs/sputum cultwith data available for four subjects aged 6–13 years
expressed as % predicted based on Polgar standards [9].
Between group comparisons were carried out using a
Wilcoxon matched pairs signed rank test, with p val-
ues<0.05% considered significant.2. Results
Culture results for individual patients and controls are
included in Tables 1a and b. All except one of the mild
group had bacterial sputum isolates, although the frequen-
cy of positive cultures was significantly less (2.8/year) than
the DF508 homozygotes (6.1/year, p<0.05). Forty six
percent of airway cultures were positive in the mild group
compared with 55% in the DF508 homozygotes. S. aureus
was cultured from 8 of the 11 patients, H. influenzae from
9 and P. aeruginosa found in 7 (64%). Three (27%) of
mildly affected patients would be considered colonised (3
or more positive cultures in 6 months). Appropriate
courses of eradication therapy were prescribed for all P.
aeruginosa positive cultures [10]. The median age at first
growth of P. aeruginosa was 1.8 years in the atypical
group and 2.0 years in patients homozygous for two severe
mutations. Lung function, in terms of FEV1, was similar in
both groups (median+range, % predicted — mild 86.5,
68–87 vs. severe 76.0, 65–88; p 0.5), although only 4
pairs were old enough to generate consistent data.
However, a trend to a higher FEV1 was seen in the mildly
affected patients who showed significantly better mean
FVC (median % predicted, mild 95, range 84–101 vs.
severe 89, range 68–116; p =0.03).
Shwachman scores (median+range) were significantly
higher in patients with mild mutations — 94, 74–92 vs.
88, 77–91; p <0.05). There was also a small but
significant difference in chest radiograph (Chrispin–Nor-
man) scores (median+range), (mild 5.1, 4–9 vs. severe
5.8, 3–10; p 0.04), although all eleven patients with mild
phenotype showed some abnormality on chest X-rayverage
hwachman
core/100
Average Chrispin–
Norman score/38
Total positive
sputum culturesa
Positive sputum
cultures/year
(mean)a
1 5 0 0
3 6 15 2.8
1.7 7 13 3.3
4.3 9 7 1.8
3.2 5.3 23 4.6
8 8
5 4 0 0
5 5.3 14 2.3
5 4.6 25 3.6
7 4 5 2.5
5.7 4.5 41 5.9
ures (age dependent).
Table 1b
Patient details for dF508 homozygote control cohort
Age Sex Genotype Average
Shwachman
score/100
Average
Chrispin–Norman
Score/25
Frequency of
positive sputum
culturesa
Positive sputum
cultures/year
(mean)a
3 Male Homozygous dF508 90.3 4.7 30 10
5 Male Homozygous dF508 88.5 5.8 33 6.6
8 Female Homozygous dF508 78.6 5.8 14 1.8
11 Female Homozygous dF508 77 10 12 1.1
7 Female Homozygous dF508 88.2 6.5 26 3.7
1 Male Homozygous dF508 78 3 2 1
5 Female Homozygous dF508 90.8 4.8 32 6.4
5 Female Homozygous dF508 80 8 30 6
6 Female Homozygous dF508 89 6.4 18 3
6 Male Homozygous dF508 88.3 6.7 72 12
7 Female Homozygous dF508 85.9 5.7 81 11.6
a Culture samples based on naso-pharyngeal aspirates/cough swabs/sputum cultures (age dependent).
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thickening.3. Discussion
Patients with both classic and mild variant CF display a
broad phenotypic range [11], with high variability among
patients carrying the same genotype and among siblings.
Variation may reflect both environmental factors and
complex interactions between numerous gene products.
The degree of correlation between CFTR genotype and
CF phenotype appears highest for pancreatic status and
lowest for pulmonary disease [12]. Atypical mild mutations
in the CFTR gene have been linked to late-onset pulmonary
disease [13]; this report, however, documents positive
sputum cultures with significant bacterial pathogens and
chest radiograph change in the majority of children with
mild variant disease.
S. aureus is a significant respiratory pathogen in patients
with CF and was isolated from the majority of the mild
variant cohort in this study. Almost one third of infants
identified through screening will have S. aureus in their
lower airway by 3 months of age [14]. Colonisation rates
vary from less than 10% in Centres using long-term
flucloxacillin prophylaxis to over 90% by 5–9 years in
Milan, where no prophylaxis is prescribed [15]. The
frequency of positive isolates can be altered by antibiotic
prophylaxis. Weaver et al. showed infants with CF
identified by neonatal screening and treated with fluclox-
acillin for the first 2 years had less cough, less need for
additional courses of antibiotics and fewer S. aureus
positive sputum cultures compared with those treated with
episodic antimicrobials as clinically indicated [16]. The
protective effect of antibiotic prophylaxis was difficult to
determine in this study because delay in diagnosis resulted
in only 4 infants with mild variant disease receiving
treatment during the first year of life. Three further children
started flucloxacillin therapy at 1, 3 and 4 years, respec-tively. While there is no clear benefit in continuing anti-
staphylococcal therapy beyond 2 years, with 73% of
patients with mild variant disease growing S. aureus from
respiratory cultures, they would appear at similar risk to
children with classic CF.
More than half grew P. aeruginosa at one time or
another. The mean age at first acquisition was similar in
both groups (1.8–2.0 years). Twenty seven percent met
current criteria for colonisation [17]. As colonisation with
P. aeruginosa is associated with the greatest risks of
shortened survival [18] and oral, nebulized and intravenous
antibiotics can prevent, eradicate or delay lower airway
colonisation and slow decline of pulmonary function
[19,20], early detection and treatment is vital to prevent
progressive lung disease.
Global assessment was carried out on both groups
annually using the Shwachman score. Even at this young
age (mean 6.5 years) there were differences between the
two groups in terms of their overall clinical condition.
However, all children with mild disease showed some
change on their chest films with comparable rates of change
in chest X-ray appearance between groups. The relatively
small number of children able to perform reliable spirom-
etry limited analysis of lung function data; however, FVC
was higher in the mild variant group and with larger
numbers it is likely that significant difference between the
two groups would emerge in terms of FEV1. There was,
nevertheless, some deviation from normal in the mild group
with FEV1 showing a rate of fall in lung function similar to
that reported in the general CF population [21]. It would be
helpful to evaluate these patients with more sensitive
measurements of lung function [22].
The majority of the study cohort were ascertained
through a neonatal screening programme and were asymp-
tomatic at diagnosis. Nevertheless, regular clinic review
with routine sputum cultures shows that there are implica-
tions for clinical management in children with mild variant
disease. Most will have bacterial isolates from sputum
requiring antibiotic therapy three to four times a year.
A. Lording et al. / Journal of Cystic Fibrosis 5 (2006) 101–104104Typical CF respiratory pathogens were isolated from all but
one of the patients with a relatively high frequency of S.
aureus and P. aeruginosa infection. There appears a strong
case for regular follow up with routine sputum cultures/
pharyngeal aspirates for patients with mild variant disease.
Prophylactic anti-staphylococcal antibiotics to 2 years
should be considered.Acknowledgement
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